284 related articles for article (PubMed ID: 29691732)
1. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
[TBL] [Abstract][Full Text] [Related]
2. Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes.
Uno T; Wada K; Matsuda S; Terada Y; Terakawa N; Oita A; Yokoyama S; Kawase A; Hosomi K; Takada M
Eur J Clin Pharmacol; 2019 Jan; 75(1):67-75. PubMed ID: 30251062
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
5. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
[TBL] [Abstract][Full Text] [Related]
9. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
13. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
Khan AR; Raza A; Firasat S; Abid A
Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
[TBL] [Abstract][Full Text] [Related]
19. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
[TBL] [Abstract][Full Text] [Related]
20. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]